Author: Abhay Panchal

Lucid Diagnostics has begun receiving Medicare payments for its EsoGuard esophageal DNA test, marking a key reimbursement milestone for the company’s esophageal precancer detection business. The company reported receiving payments at the established Clinical Laboratory Fee Schedule rate of $1,938.01 per test, following its September announcement that it would begin submitting Medicare claims through one of its CLIA-certified laboratories. EsoGuard analyzes DNA markers associated with esophageal precancer using samples collected with the EsoCheck esophageal cell collection device, a noninvasive office-based procedure. The test is intended to help identify esophageal precancer in at-risk patients, including those with gastroesophageal reflux disease (GERD).…

Read More

A new study published in Gastroenterology highlights gaps in ambulatory training for gastroenterology fellows in the United States. Although most GI care is delivered in outpatient settings, less than 10% of fellowship training is required to take place in ambulatory environments. Researchers recommend developing a standardized curriculum to better prepare trainees for outpatient practice. Led by Amy Ogurick, MD, assistant professor of medicine at Yale School of Medicine, the study surveyed current GI fellows, recent graduates, and fellowship program directors. Participants assessed training practices, educational barriers, and confidence across 34 common ambulatory topics, including irritable bowel syndrome and hemorrhoids. One…

Read More

VIOVOC has received U.S. Patent No. 12,761,175 for technology designed to detect volatile organic compounds (VOCs) in bathroom air and translate these signals into personalized dietary guidance. The company’s ambient sensor is designed to passively monitor compounds associated with gut microbial activity without requiring stool samples, test kits, or food diaries. The device uses a metal oxide sensor to detect changes in electrical resistance caused by VOCs in ambient air. Measurements are transmitted wirelessly to a server and compared with an individual’s personalized baseline to generate dietary recommendations. The system powers VIOVOC’s Virtual Fiber Coach, which uses a proprietary V-Factor…

Read More

Geneoscopy has launched ColoSense NextStep, an opt-in patient navigation program designed to help patients with positive results from its ColoSense colorectal cancer (CRC) screening test complete recommended follow-up colonoscopy. The initiative addresses a persistent gap in screening: a study of nearly 33,000 people with positive stool-based screening results found that only 56% received a follow-up colonoscopy within one year. Research has also linked failure to complete follow-up after a positive stool-based test with twice the risk of death from colorectal cancer. The provider-enabled program offers consent-based outreach through text, email, or phone. Its clinical support team provides general education about…

Read More

Gastroenterologists have overtaken orthopedic surgeons as the highest-paid physician recruits in the United States, with an average starting salary of $654,000, according to AMN Healthcare’s 2026 Review of Physician and Advanced Practitioner Recruiting Incentives. This represents an 18.5% increase year over year. Orthopedic surgeons’ average starting salaries fell 12% to $507,000, while interventional cardiologists ranked second at $650,000. The report found that average starting salaries across all physicians rose to $419,000, up from $403,000 the previous year. Physician signing bonuses increased 29% to $49,306, with bonuses offered in 87% of AMN Healthcare’s physician recruiting engagements, compared with 74% a year…

Read More

The updated STRIDE-III recommendations refine the international treat-to-target framework for Crohn’s disease and ulcerative colitis, incorporating new evidence on inflammatory outcomes and patient-centered measures. The update draws on a systematic review that included 1,018 studies, alongside surveys of adult and pediatric gastroenterology experts. The framework distinguishes three categories of treatment targets. Actionable targets include clinical response and remission, C-reactive protein normalization, fecal calprotectin within the target range, and endoscopic remission. Adjunctive targets, such as urgency, histological remission in ulcerative colitis, transmural remission in Crohn’s disease, and growth, help guide treatment optimization and monitoring but do not necessarily require a change…

Read More

A retrospective analysis of more than 30,000 screening participants, presented at the American College of Gastroenterology (ACG) 2026 Annual Scientific Meeting, found that fecal immunochemical testing (FIT) was less sensitive for colorectal cancer (CRC) and advanced precancerous lesions in women than in men at the standard positivity threshold. Using a threshold of 100 ng/mL, FIT detected 62.0% of CRC cases in women, compared with 77.4% in men. Sensitivity for advanced precancerous lesions was also lower in women (20.2% versus 25.8%). The difference was particularly pronounced for proximal CRC, where sensitivity was 50.0% in women and 80.8% in men. Women also…

Read More

Greg O’Grady, professor of surgery at the University of Auckland and co-founder and CEO of Alimetry, left surgical practice in 2021 to develop technology aimed at improving the diagnosis of functional stomach disorders. His company’s Gastric Alimetry is a prescription, wearable test that maps the stomach’s electrical activity through 64 adhesive electrodes placed on the upper abdomen. During a roughly four-and-a-half-hour assessment that includes a standard meal, the system records gastric electrical rhythms and correlates them with patient-reported symptoms—without endoscopy, tubes or radiation. The technology is designed to help investigate symptoms such as chronic nausea, vomiting, early fullness and post-meal…

Read More

Jiro Health’s Gastroenterology Practice Economics Benchmark 2026 highlights two financial pressures facing gastroenterology practices: differences in reimbursement linked to practice scale and substantial payment reductions for additional procedures performed during the same visit. The analysis found that 20.7% of additional GI procedures received less than 25% of their standard standalone rate, the highest share among the specialties measured. Gastroenterologists typically received approximately 32%–38% of the standard rate for a second procedure, while 28.4% of GI visits included two or more procedures. The report attributed much of the reduction to Medicare’s same-scope payment rule, which accounts for shared procedural work, and…

Read More

Throne Science presented its first clinical validation study at the 2026 American College of Gastroenterology (ACG) Annual Scientific Meeting, evaluating an AI model that classifies stool using the Bristol Stool Scale (BSS). The study compared the model’s classifications with assessments from five gastroenterologists using 278 real-world images collected from beta testers across all seven BSS categories. For the most common stool type, BSS Type 4, the AI model achieved 89.6% exact-match agreement, compared with a 59.9% human-to-human agreement baseline. Throne’s toilet-mounted sensor is designed to passively track bowel movements, hydration and urinary function, providing continuous data that could help clinicians…

Read More